Combating malaria drug resistance with new treatment combinations
Dual artemisinin action combats resistance
This study is looking at how to combine two types of malaria medications to create better treatments for people dealing with tough strains of the disease, so patients can have more effective options to fight malaria.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11035063 on NIH RePORTER |
What this research studies
This research focuses on developing effective combinations of artemisinin and quinoline drugs to combat malaria caused by the P. falciparum parasite. It aims to understand how these drugs work together to overcome resistance that has developed against current treatments. By studying the interactions of these drugs at a molecular level, the research seeks to identify optimal combinations that can effectively kill the malaria parasite. Patients may benefit from new treatment options that are more effective against resistant strains of malaria.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with malaria, particularly those infected with drug-resistant strains of the P. falciparum parasite.
Not a fit: Patients with malaria caused by non-P. falciparum species or those who do not have drug-resistant malaria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective malaria treatments that can overcome drug resistance.
How similar studies have performed: Previous research has shown promise in using combination therapies to combat drug resistance in malaria, indicating that this approach could be effective.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Sullivan, David Joseph — Johns Hopkins University
- Study coordinator: Sullivan, David Joseph
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.